Marker Therapeutics MRKR 深 沪
等待开盘 09-18 09:30:00 美东时间
0.9503
-0.044
-4.47%
华盛通- 最 高1.02
- 今 开0.9921
- 成交量 16.67万股
- 最 低 0.95
- 昨 收 0.9948
- 总市值 1229.58万
- 52周最高 5.95
- 市盈率 静 --
- 换手率 1.29%
- 52周最低 0.8099
- 委 比 -26.29%
- 总股本 1293.89万
- 历史最高 99.00
- 量 比 0.45
- 振 幅 7.04%
- 历史最低 0.8099
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Phase 1 APOLLO study of MT-601 shows 66% objective response rate in NHL patients, with 50% achieving complete response. The treatment demonstrated a favorable safety profile, with no dose-limiting toxicities or ICANS. The study will expand to investigate MT-601 at the maximum dose in DLBCL patients who relapsed after or are ineligible for CAR-T therapy. A live webcast discussing the results will be held today.
08-26 11:00
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Marker Therapeutics' CEO, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The session will focus on the Company's MAR T cell platform and clinical developments. Investors can access the webcast via Marker's Investor Relations website.
07-30 12:00
Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor
06-17 20:08
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Marker Therapeutics collaborates with Cellipont Bioservices to manufacture MT-601, a Multi-Antigen Recognizing T cell therapy for lymphoma patients. MT-601 has shown promising results in the Phase 1 APOLLO study, with 78% of participants experiencing objective responses. The partnership aims to accelerate clinical supply and prepare for potential pivotal trials. Both companies emphasize their commitment to advancing innovative immunotherapies to ...
06-17 12:00
Marker Therapeutics Concludes Annual Stockholders Meeting
Marker Therapeutics ( ($MRKR) ) just unveiled an update. On June 6, 2025, Marke...
06-10 04:28
Marker Therapeutics To Highlight Multi-Antigen Recognizing-T Cells In High-Profile Panel On CAR-T Cell Therapies
MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid
05-19 20:10
美股大行评级 | 潜在涨幅4159%！HC Wainwright & Co.上调BiomX目标价至21美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1114111385008877568.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BiomX(PHGE)"买入"评级，目标价从2美元升至21美元</p> <p>• HC Wainwright & Co.：维持Unicycive Therapeu
04-02 09:42
美股机会日报丨美股期指大跌！华尔街模型预测衰退概率最高达50%
美股指数盘前重挫！标普500指数期货跌1.25%，英伟达跌超3%；华尔街模型预测衰退概率最高达50%；京东盘前涨超6%，拟回购最多50亿美元股票>>
03-06 21:11
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
Marker Therapeutics Grants Stock Options to Directors
Marker Therapeutics ( ($MRKR) ) has provided an announcement. On February 12, 2...
02-20 06:29
